New hope for lung cancer patients who failed targeted treatment?

NCT ID NCT07158840

Not yet recruiting Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study tests a drug called AK112 in 60 people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has specific genetic changes and has stopped responding to previous targeted therapy. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also track how long patients live and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AK112 (a drug that helps the immune system fight cancer)
What this could lead to: If successful, this could offer a new treatment option for people with a specific type of lung cancer who have stopped responding to standard targeted therapy.
What could go wrong: This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Guangdong Provincial People's Hospital

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.